Commercial
  
  
  
  
  
  
  
  
  
  
MPattachmentdataPub
8d777768-65bb-4b72-8681-5bc568ba8782.aspx
  
08.00.62mAbatacept(Orencia®)forInjectionforIntravenousUse08.00.62mPharmacy (08)Abatacept (Orencia®) for Injection for Intravenous Use8d777768-65bb-4b72-8681-5bc568ba87823542Abatacept (Orencia®) for Injection for Intravenous Use08.00.62
{"3543": {"Id":3543,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":5693,"PolicyAttachmentPageName":"b5270336-b546-46c9-a742-ffbf76936bc7"},}
9b891878-088a-46b3-87eb-d2032e21e161.aspx
  
12.00.01fAcupuncture(Independence)12.00.01fMiscellaneous (12)Acupuncture (Independence)9b891878-088a-46b3-87eb-d2032e21e1613177Acupuncture (Independence)12.00.01
{"3178": {"Id":3178,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Acupuncture","MPPolicyAttachmentInternalSourceId":5410,"PolicyAttachmentPageName":"0c7269c3-4107-4e68-a3d6-0913e0b02dcd"},}
151d34b6-4e58-416b-b105-5282cd83c5f4.aspx
  
12.00.01gAcupuncture(Independence)12.00.01gMiscellaneous (12)Acupuncture (Independence)151d34b6-4e58-416b-b105-5282cd83c5f43625Acupuncture (Independence)12.00.01
{"3626": {"Id":3626,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Acupuncture","MPPolicyAttachmentInternalSourceId":5770,"PolicyAttachmentPageName":"162a73bf-e53e-4008-9b6f-f3b142e31096"},}
a26ef448-30db-43ac-94c2-e6d4b2be4b3a.aspx
  
12.04.04aAcuteCareFacilityInpatientTransfers12.04.04aMiscellaneous (12)Acute Care Facility Inpatient Transfersa26ef448-30db-43ac-94c2-e6d4b2be4b3a3272Acute Care Facility Inpatient Transfers12.04.04
7d2c9273-a6c7-4c55-829b-131f19dcc536.aspx
  
08.01.11gAdo-TrastuzumabEmtansine(Kadcyla®)08.01.11gPharmacy (08)Ado-Trastuzumab Emtansine (Kadcyla®)7d2c9273-a6c7-4c55-829b-131f19dcc5363832Ado-Trastuzumab Emtansine (Kadcyla®)08.01.11
{"3833": {"Id":3833,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes and Narratives","MPPolicyAttachmentInternalSourceId":5900,"PolicyAttachmentPageName":"cc304fe8-ebb1-430f-921d-46e18337efdd"},}
119a4599-f16d-4baf-b41b-f1bce92d9fcc.aspx
  
08.00.69cAgalsidasebeta(Fabrazyme®)08.00.69cPharmacy (08)Agalsidase beta (Fabrazyme®)119a4599-f16d-4baf-b41b-f1bce92d9fcc3510Agalsidase beta (Fabrazyme®)08.00.69
225d3101-03b1-4bcf-bbb9-96b94e93d897.aspx
  
12.04.03cAirAmbulanceServices12.04.03cMiscellaneous (12)Air Ambulance Services225d3101-03b1-4bcf-bbb9-96b94e93d8973340Air Ambulance Services12.04.03
73aa91d4-6dd1-4f04-aca2-d73e96227091.aspx
  
08.01.22dAlemtuzumab(Lemtrada®)08.01.22dPharmacy (08)Alemtuzumab (Lemtrada®)73aa91d4-6dd1-4f04-aca2-d73e962270913349Alemtuzumab (Lemtrada®)08.01.22
9ddca8f7-84ab-49ea-83b9-9743aa009617.aspx
  
08.00.72jAlglucosidasealfa(e.g.,Lumizyme®),Avalglucosidasealfa-ngpt(Nexviazyme®)08.00.72jPharmacy (08)Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® )9ddca8f7-84ab-49ea-83b9-9743aa0096173961Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® )08.00.72
ed39b1c3-6d7a-468f-a34f-d38ae5a9c7b9.aspx
  
07.00.21jAllergyImmunotherapy07.00.21jMedicine (07)Allergy Immunotherapyed39b1c3-6d7a-468f-a34f-d38ae5a9c7b93158Allergy Immunotherapy07.00.21
50885de3-59ab-43a6-9222-a0a4e00c9908.aspx
  
06.02.29dAlloMap™MolecularExpressionTestingforHeartTransplantRejection(IndependenceAdministrators)06.02.29dPathology and Laboratory (06)AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)50885de3-59ab-43a6-9222-a0a4e00c99083169AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)06.02.29
0e1c37c2-8647-4bf9-83de-aa2f822a38df.aspx
  
08.00.91eAlpha1-AntitrypsinTherapy(e.g.,Prolastin-C®,AralastNP®,Glassia®,Zemaira®)08.00.91ePharmacy (08)Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®)0e1c37c2-8647-4bf9-83de-aa2f822a38df3783Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®)08.00.91
8e6b2fec-4b4a-4ae8-89fc-085134c007c0.aspx
  
00.01.52oAlwaysBundledProcedureCodes00.01.52oAdministrative (00)Always Bundled Procedure Codes8e6b2fec-4b4a-4ae8-89fc-085134c007c03978Always Bundled Procedure Codes00.01.52
{"3979": {"Id":3979,"MPAttachmentLetter":"B","Title":"Procedures/Services Not Eligible for Separate Reimbursement","MPPolicyAttachmentInternalSourceId":6124,"PolicyAttachmentPageName":"a233dba9-5846-4c68-a5a5-c8ea0f479c64"},"3980": {"Id":3980,"MPAttachmentLetter":"A","Title":"Always Bundled Procedures (Indicator B)","MPPolicyAttachmentInternalSourceId":6125,"PolicyAttachmentPageName":"5d9878a3-f64d-4328-a391-880b1d30def0"},"3981": {"Id":3981,"MPAttachmentLetter":"C","Title":"Procedures/Services Not Eligible for Reimbursement","MPPolicyAttachmentInternalSourceId":6126,"PolicyAttachmentPageName":"e54cec8f-601c-4aac-bea4-562a36479700"},}
fadd0242-f323-49fe-8ca7-2112b67a09c4.aspx
  
07.02.09gAmbulatoryBloodPressureMonitoring(ABPM)andHomeBloodPressureMonitoring(HBPM)Devices07.02.09gMedicine (07)Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devicesfadd0242-f323-49fe-8ca7-2112b67a09c43006Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices07.02.09
4df933c3-6356-4ea5-b86d-a751cf0ba12b.aspx
  
07.02.21hAmbulatoryElectrocardiography(AECG)MonitoringandMobileCardiacOutpatientTelemetry(MCOT)Monitoring07.02.21hMedicine (07)Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring4df933c3-6356-4ea5-b86d-a751cf0ba12b3909Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring07.02.21
1ac0451d-5329-49e8-9417-dcdf7bf9dbc2.aspx
  
08.01.82aAnifrolumab-fnia(Saphnelo™)08.01.82aPharmacy (08)Anifrolumab-fnia (Saphnelo™)1ac0451d-5329-49e8-9417-dcdf7bf9dbc23968Anifrolumab-fnia (Saphnelo™)08.01.82
cf9faf96-487d-47c2-bd76-bc70fd056a33.aspx
  
05.00.39rAnkle-Foot/Knee-Ankle-FootOrthoses05.00.39rDME (05)Ankle-Foot/Knee-Ankle-Foot Orthosescf9faf96-487d-47c2-bd76-bc70fd056a333409Ankle-Foot/Knee-Ankle-Foot Orthoses05.00.39
{"3410": {"Id":3410,"MPAttachmentLetter":"A","Title":"HCPCS Codes","MPPolicyAttachmentInternalSourceId":5437,"PolicyAttachmentPageName":"5f6e2c31-1bcc-46e6-9727-fc05459b2621"},}
36aee0bb-d271-4e94-8256-eafdfce45397.aspx
  
06.03.04nApheresisTherapy06.03.04nPathology and Laboratory (06)Apheresis Therapy36aee0bb-d271-4e94-8256-eafdfce453972774Apheresis Therapy06.03.04
54a55051-84a7-467e-9137-ae398be2bf06.aspx
  
11.08.05gApplicationandRemovalofTattoos11.08.05gSurgery (11)Application and Removal of Tattoos54a55051-84a7-467e-9137-ae398be2bf063727Application and Removal of Tattoos11.08.05
202addae-a8d3-482f-b7b2-e3af034fa355.aspx
  
08.01.41cAprepitant(Cinvanti™),FosaprepitantDimeglumine(Emend®),Granisetron(Sustol®),andRolapitant(Varubi®)08.01.41cPharmacy (08)Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®)202addae-a8d3-482f-b7b2-e3af034fa3553470Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®)08.01.41
{"3471": {"Id":3471,"MPAttachmentLetter":"A","Title":"Risk of Emesis Without Prophylaxis: Intravenous and Oral Antineoplastic Agents","MPPolicyAttachmentInternalSourceId":5660,"PolicyAttachmentPageName":"00411fd3-0b49-4077-9c80-e7d25e6698cf"},}
05720d8e-7925-4a18-9aac-a0d2841e1415.aspx
  
11.05.16jAqueousShunts,Microstents,Viscocanalostomy,andCanaloplastyfortheTreatmentofGlaucoma11.05.16jSurgery (11)Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma05720d8e-7925-4a18-9aac-a0d2841e14153947Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma11.05.16
{"3948": {"Id":3948,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":6070,"PolicyAttachmentPageName":"d3ea1441-49e3-40e0-b49c-4e8c06b7da29"},}
b0e984df-bd5e-4e0d-85e6-c2a0b64cb49d.aspx
  
11.14.19pArtificialIntervertebralCervicalDiscInsertion(IndependenceAdministrators)11.14.19pSurgery (11)Artificial Intervertebral Cervical Disc Insertion (Independence Administrators)b0e984df-bd5e-4e0d-85e6-c2a0b64cb49d3704Artificial Intervertebral Cervical  Disc Insertion (Independence Administrators)11.14.19
5d023597-bc1e-40ec-8616-4e86387f03a2.aspx
  
11.15.31ArtificialIntervertebralLumbarDiscInsertion11.15.31Surgery (11)Artificial Intervertebral Lumbar Disc Insertion5d023597-bc1e-40ec-8616-4e86387f03a23666Artificial Intervertebral Lumbar Disc Insertion11.15.31
f3236241-d962-4d30-8d8c-9d77386611ed.aspx
  
08.01.35eAsparaginaseErwiniaChrysanthemi(Erwinaze®),asparaginaseerwiniachrysanthemi(recombinant)-rywn(Rylaze™)08.01.35ePharmacy (08)Asparaginase Erwinia Chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™)f3236241-d962-4d30-8d8c-9d77386611ed3962Asparaginase Erwinia Chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™)08.01.35
55d72c9f-4d95-4b4a-862a-31671d02d048.aspx
  
06.02.27mAssaysofGeneticExpressioninTumorTissueforBreastCancerPrognosis(IndependenceAdministrators)06.02.27mPathology and Laboratory (06)Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (Independence Administrators)55d72c9f-4d95-4b4a-862a-31671d02d0483922Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (Independence Administrators)06.02.27
a27db102-bd23-420f-a9fd-c5c995a63b0a.aspx
  
07.10.06iAssistedReproductiveTechnologyforInfertilityandOocyteCryopreservation07.10.06iMedicine (07)Assisted Reproductive Technology for Infertility and Oocyte Cryopreservationa27db102-bd23-420f-a9fd-c5c995a63b0a3779Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation07.10.06
718ec7af-0c6e-4a4e-8f6d-883490f0c164.aspx
  
08.01.69aAtezolizumab(Tecentriq®)08.01.69aPharmacy (08)Atezolizumab (Tecentriq®)718ec7af-0c6e-4a4e-8f6d-883490f0c1643508Atezolizumab (Tecentriq®)08.01.69
{"3509": {"Id":3509,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":5655,"PolicyAttachmentPageName":"914e332c-7a2c-46dc-91cd-1cde4190ec52"},}
c9c7224c-29eb-42be-979a-00752302dd1e.aspx
  
11.14.06jAutologousChondrocyteImplantation(ACI)andOtherCell-basedTreatmentsofFocalArticularCartilageLesions(IndependenceAdministrators)11.14.06jSurgery (11)Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Independence Administrators)c9c7224c-29eb-42be-979a-00752302dd1e3734Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Independence Administrators)11.14.06
6e37e5d6-bbaf-48fa-a6c3-063563373e0a.aspx
  
05.00.29lAutomaticExternalCardioverterDefibrillators(WearableandNonwearable)05.00.29lDME (05)Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)6e37e5d6-bbaf-48fa-a6c3-063563373e0a3492Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)05.00.29
{"3493": {"Id":3493,"MPAttachmentLetter":"B","Title":"ICD-10 codes used to represent the Nonwearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":5694,"PolicyAttachmentPageName":"6cb3f087-d8e1-46f2-bb16-e4c0efccf069"},"3494": {"Id":3494,"MPAttachmentLetter":"A","Title":"ICD-10 Codes used to represent the Wearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":5695,"PolicyAttachmentPageName":"663a7b01-481b-406b-a86b-acc389b6356f"},}
d0e8482f-b787-4f4e-8792-f95be3cce0c1.aspx
  
07.03.23eAutonomicNervousSystemTesting07.03.23eMedicine (07)Autonomic Nervous System Testingd0e8482f-b787-4f4e-8792-f95be3cce0c13931Autonomic Nervous System Testing07.03.23
24beb3c0-be00-4c64-b472-cc607163e0e4.aspx
  
08.01.64aAvelumab(Bavencio®)08.01.64aPharmacy (08)Avelumab (Bavencio®)24beb3c0-be00-4c64-b472-cc607163e0e43955Avelumab (Bavencio®)08.01.64
{"3956": {"Id":3956,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":6026,"PolicyAttachmentPageName":"5e1d79c5-0a19-44be-aa57-7eec4d94d63c"},}
f8443122-4304-4580-b9b5-989ddd993559.aspx
  
11.16.06jBalloonCatheterDilationofSinusOstiaforTreatmentofChronicRhinosinusitis11.16.06jSurgery (11)Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitisf8443122-4304-4580-b9b5-989ddd9935593785Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis11.16.06
e2e22104-ada2-4d84-9c71-c600f1ea170e.aspx
  
11.03.02tBariatricSurgery11.03.02tSurgery (11)Bariatric Surgerye2e22104-ada2-4d84-9c71-c600f1ea170e2791Bariatric Surgery11.03.02
{"2792": {"Id":2792,"MPAttachmentLetter":"A","Title":"Body Mass Index (BMI) Charts","MPPolicyAttachmentInternalSourceId":4907,"PolicyAttachmentPageName":"292a20ba-ec48-442c-a624-40100880cb31"},"2793": {"Id":2793,"MPAttachmentLetter":"B","Title":"Tanner Staging System Criteria for Adolescents","MPPolicyAttachmentInternalSourceId":4908,"PolicyAttachmentPageName":"1b6da816-a2b6-4583-807a-5430c89f8392"},"2794": {"Id":2794,"MPAttachmentLetter":"C","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":4909,"PolicyAttachmentPageName":"b9184a36-7491-498e-aac9-ed1933abf92b"},}
bde34a1a-c1f2-4778-b78a-72050d24e484.aspx
  
08.01.70bBelantamabmafodotin-blmf(Blenrep)08.01.70bPharmacy (08)Belantamab mafodotin-blmf (Blenrep)bde34a1a-c1f2-4778-b78a-72050d24e4843176Belantamab mafodotin-blmf (Blenrep)08.01.70
a538b471-570c-403b-9114-cc764e9fba6a.aspx
  
08.00.99dBelimumab(Benlysta®)forIntravenousUse08.00.99dPharmacy (08)Belimumab (Benlysta®) for Intravenous Usea538b471-570c-403b-9114-cc764e9fba6a3036Belimumab (Benlysta®) for Intravenous Use08.00.99
e5743575-3866-4edc-bdc2-d245636c2623.aspx
  
08.00.66pBevacizumab(Avastin®)andRelatedBiosimilarsForOncologicUse08.00.66pPharmacy (08)Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Usee5743575-3866-4edc-bdc2-d245636c26233552Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use08.00.66
{"3553": {"Id":3553,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":5779,"PolicyAttachmentPageName":"ac3aa4c9-d963-45d8-8266-8a9f48e65f6e"},}
51aaf4af-1813-47af-95b8-8602dee4fdf0.aspx
  
00.10.39oBillingforProfessionalOffice-BasedServicesPerformedinanOutpatientOffice-BasedSettingLocatedwithinaFacilityoronaFacilityCampus00.10.39oAdministrative (00)Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus51aaf4af-1813-47af-95b8-8602dee4fdf03975Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus00.10.39
{"3976": {"Id":3976,"MPAttachmentLetter":"A","Title":"Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus","MPPolicyAttachmentInternalSourceId":6119,"PolicyAttachmentPageName":"9e4f9d52-c926-4fc8-81c9-1f2f4cc888d5"},}
7467b7be-328a-4664-89ab-13b4c0859839.aspx
  
00.10.38aBillingRequirementsforMultipleBirthsforProfessionalProviders00.10.38aAdministrative (00)Billing Requirements for Multiple Births for Professional Providers7467b7be-328a-4664-89ab-13b4c08598393051Billing Requirements for Multiple Births for Professional Providers00.10.38
{"3052": {"Id":3052,"MPAttachmentLetter":"A","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ROUTINE OBSTETRIC (GLOBALE MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":5340,"PolicyAttachmentPageName":"d157b661-7eea-46ea-ab0f-b6ec2bd15a87"},"3053": {"Id":3053,"MPAttachmentLetter":"B","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ANETEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":5341,"PolicyAttachmentPageName":"5d22c25e-12c7-42e4-a127-e50b59895309"},"3054": {"Id":3054,"MPAttachmentLetter":"C","Title":"CODING SCENARIOS FOR REPORTING HIGH-ORDER MULTIPLE (TRIPLETS, QUADRUPLETS, ETC) BIRTHS WHEN ROUTINE OBSTETRIC (GLOBAL MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":5342,"PolicyAttachmentPageName":"d0a0d176-67d6-4d41-9e52-2cbec1ebff3d"},"3055": {"Id":3055,"MPAttachmentLetter":"D","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF HIGH-ORDER MULTIPLES WHEN ANTEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":5343,"PolicyAttachmentPageName":"74d58125-3d75-4d7b-8d89-cbaebd03cc03"},}
c953a697-6789-487c-85c5-74cc02b327f3.aspx
  
07.00.01jBiofeedbackTherapy07.00.01jMedicine (07)Biofeedback Therapyc953a697-6789-487c-85c5-74cc02b327f33669Biofeedback Therapy07.00.01
6b56ce1e-6818-41bb-9061-330aebb8ecf5.aspx
  
07.06.03bBioimpedencefortheDetectionofLymphedema07.06.03bMedicine (07)Bioimpedence for the Detection of Lymphedema6b56ce1e-6818-41bb-9061-330aebb8ecf53321Bioimpedence for the Detection of Lymphedema07.06.03
bb4a7aab-8e51-48b8-b70e-d9723cca3441.aspx
  
11.05.02jBlepharoplasty,RepairofBlepharoptosis,RepairofBrowPtosis,andCanthoplasty/Canthopexy11.05.02jSurgery (11)Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexybb4a7aab-8e51-48b8-b70e-d9723cca34413770Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexy11.05.02
{"3771": {"Id":3771,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5915,"PolicyAttachmentPageName":"bb9ab1fd-6bf0-4cdc-9739-4a2c84da817c"},}
2d06cc9f-7fee-4974-8d3b-5354317cf365.aspx
  
08.01.21dBlinatumomab(Blincyto®)08.01.21dPharmacy (08)Blinatumomab (Blincyto®)2d06cc9f-7fee-4974-8d3b-5354317cf3653287Blinatumomab (Blincyto®)08.01.21
cc074a4c-e78d-48cd-853e-9f582fa3102a.aspx
  
11.01.06fBone-Anchored(Osseointegrated)HearingAidsandImplantableMiddleEarHearingAids11.01.06fSurgery (11)Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aidscc074a4c-e78d-48cd-853e-9f582fa3102a3984Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids11.01.06
e2d89fb6-24ef-4a16-a953-2d2451aaa404.aspx
  
09.00.04lBoneMineralDensity(BMD)Testing09.00.04lRadiology (09)Bone Mineral Density (BMD) Testinge2d89fb6-24ef-4a16-a953-2d2451aaa4043911Bone Mineral Density (BMD) Testing09.00.04
baa812b2-43e6-4cff-82b5-9592a674f59e.aspx
  
08.00.73mBortezomib(BortezomibforInjection,Velcade®)08.00.73mPharmacy (08)Bortezomib (Bortezomib for Injection, Velcade®)baa812b2-43e6-4cff-82b5-9592a674f59e3150Bortezomib (Bortezomib for Injection, Velcade®)08.00.73
f3a2fbd3-38cb-431f-8734-441b29bf1dfa.aspx
  
08.00.26xBotulinumToxinAgents08.00.26xPharmacy (08)Botulinum Toxin Agentsf3a2fbd3-38cb-431f-8734-441b29bf1dfa3171Botulinum Toxin Agents08.00.26
{"3172": {"Id":3172,"MPAttachmentLetter":"A","Title":"ICD-10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":5156,"PolicyAttachmentPageName":"b99590fc-80da-417b-b8a5-4da094ad7d28"},}
4cb3894b-2c2b-4737-a0c4-1ba6c6a65167.aspx
  
09.00.10zBrachytherapyandAcceleratedWholeBreastIrradiationusingThree-DimensionalConformationRadiationTherapy09.00.10zRadiology (09)Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy4cb3894b-2c2b-4737-a0c4-1ba6c6a651673041Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy09.00.10
6e801976-dd85-4167-87f9-dcdee3a4f0c7.aspx
  
05.00.76eBreastPumps05.00.76eDME (05)Breast Pumps6e801976-dd85-4167-87f9-dcdee3a4f0c73849Breast Pumps05.00.76
87590db1-6d5c-4464-88c7-ad4cf440f953.aspx
  
08.01.13fBrentuximabVedotin(Adcetris®)08.01.13fPharmacy (08)Brentuximab Vedotin (Adcetris®)87590db1-6d5c-4464-88c7-ad4cf440f9533550Brentuximab Vedotin (Adcetris®)08.01.13
{"3551": {"Id":3551,"MPAttachmentLetter":"A","Title":"ICD CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":5777,"PolicyAttachmentPageName":"a3d243de-946f-412f-812a-07d699556559"},}
d7f202d9-ab28-404f-adf1-0798651bfeb6.aspx
  
08.01.49bBurosumab-twza(Crysvita®)08.01.49bPharmacy (08)Burosumab-twza (Crysvita®)d7f202d9-ab28-404f-adf1-0798651bfeb63034Burosumab-twza (Crysvita®)08.01.49
38d30b81-d6e8-498c-bccd-3c3f2baa02a4.aspx
  
08.01.51aCanakinumab(Ilaris®)08.01.51aMiscellaneous (12)Canakinumab (Ilaris®)38d30b81-d6e8-498c-bccd-3c3f2baa02a43000Canakinumab (Ilaris®)08.01.51
70f913cb-a2d4-40de-ba99-3b2938c110b7.aspx
  
10.01.01nCardiacRehabilitation(CR)andIntensiveCardiacRehabilitation(ICR)Programs10.01.01nRehabilitation Services (10)Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs70f913cb-a2d4-40de-ba99-3b2938c110b73672Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs10.01.01
{"3673": {"Id":3673,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5729,"PolicyAttachmentPageName":"9edc8373-3d61-4d0c-9158-b0716b073418"},}
41a2fd36-17bd-4939-a95f-d6b98c255174.aspx
  
00.01.59iCareManagementandCarePlanningServices00.01.59iAdministrative (00)Care Management and Care Planning Services41a2fd36-17bd-4939-a95f-d6b98c2551743983Care Management and Care Planning Services00.01.59
43d9008a-91ea-42cb-8a77-52594e9adc9f.aspx
  
08.01.05hCarfilzomib(Kyprolis®)08.01.05hPharmacy (08)Carfilzomib (Kyprolis®)43d9008a-91ea-42cb-8a77-52594e9adc9f3831Carfilzomib (Kyprolis®)08.01.05
9a58b2c2-ac51-4f36-b633-45311f346cea.aspx
  
00.10.15dCastandSplintApplicationsandAssociatedSupplies00.10.15dAdministrative (00)Cast and Splint Applications and Associated Supplies9a58b2c2-ac51-4f36-b633-45311f346cea2782Cast and Splint Applications and Associated Supplies00.10.15
{"2783": {"Id":2783,"MPAttachmentLetter":"A","Title":"Procedure Codes Related to Cast and Splint Applications and Associated Supplies","MPPolicyAttachmentInternalSourceId":4979,"PolicyAttachmentPageName":"0e216c08-2117-49fb-87c3-6ff39b233cd3"},}
437e90bf-4f5d-44ae-ad6a-f798ebf1031e.aspx
  
11.01.07fCataractSurgery11.01.07fSurgery (11)Cataract Surgery437e90bf-4f5d-44ae-ad6a-f798ebf1031e3932Cataract Surgery11.01.07
{"3933": {"Id":3933,"MPAttachmentLetter":"A","Title":"ICD 10 codes for policy 11.01.07d, Cataract Surgery","MPPolicyAttachmentInternalSourceId":6072,"PolicyAttachmentPageName":"599939d0-daf9-4f13-8d68-e4a1412ea6d6"},}
03ddb112-9c09-44e9-a171-b7205733aeaa.aspx
  
11.02.06nCatheterAblationofCardiacArrhythmias11.02.06nSurgery (11)Catheter Ablation of Cardiac Arrhythmias03ddb112-9c09-44e9-a171-b7205733aeaa3938Catheter Ablation of Cardiac Arrhythmias11.02.06
15a5a238-fa34-4075-a0b2-5da6f2983c7f.aspx
  
08.01.66aCemiplimab-rwlc(Libtayo®)08.01.66aPharmacy (08)Cemiplimab-rwlc (Libtayo®)15a5a238-fa34-4075-a0b2-5da6f2983c7f3959Cemiplimab-rwlc (Libtayo®)08.01.66
d0bf9cac-5008-4f9d-a225-598e388f07d8.aspx
  
08.01.39cCerliponasealfa(Brineura®)08.01.39cPharmacy (08)Cerliponase alfa (Brineura®)d0bf9cac-5008-4f9d-a225-598e388f07d83188Cerliponase alfa (Brineura®)08.01.39
be2a151d-873a-4328-9ba2-f47270b2fafb.aspx
  
05.00.61gCervicalTractionDevicesforIn-homeUse05.00.61gDME (05)Cervical Traction Devices for In-home Usebe2a151d-873a-4328-9ba2-f47270b2fafb3803Cervical Traction Devices for In-home Use05.00.61
cdbc995f-3e19-494b-8ec1-a6cffbb1b055.aspx
  
08.00.67mCetuximab(Erbitux®)08.00.67mPharmacy (08)Cetuximab (Erbitux®)cdbc995f-3e19-494b-8ec1-a6cffbb1b0553500Cetuximab (Erbitux®)08.00.67
{"3501": {"Id":3501,"MPAttachmentLetter":"B","Title":"ICD-10 Codes for Cetuximab (Erbitux®)","MPPolicyAttachmentInternalSourceId":5391,"PolicyAttachmentPageName":"0782f068-f334-4ef3-8575-fcdd56442627"},"3502": {"Id":3502,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":5392,"PolicyAttachmentPageName":"adcb6987-3065-4605-a151-afd058941acf"},}
c9c846c6-7feb-44a7-bccc-e1a79d2f0ddf.aspx
  
11.08.08gChemicalPeels11.08.08gSurgery (11)Chemical Peelsc9c846c6-7feb-44a7-bccc-e1a79d2f0ddf3516Chemical Peels11.08.08
07c40c18-7aef-4330-8935-16635f2ebf67.aspx
  
08.01.43jChimericAntigenReceptor(CAR)Therapy08.01.43jPharmacy (08)Chimeric Antigen Receptor (CAR) Therapy07c40c18-7aef-4330-8935-16635f2ebf673923Chimeric Antigen Receptor (CAR) Therapy08.01.43
{"3924": {"Id":3924,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":6115,"PolicyAttachmentPageName":"699d305b-2a53-480e-a300-2ca122f8de0d"},}
c042c02a-0451-49be-a2c5-a513ea157169.aspx
  
10.02.02jChiropracticSpinalandExtraspinalManipulationTherapy10.02.02jRehabilitation Services (10)Chiropractic Spinal and Extraspinal Manipulation Therapyc042c02a-0451-49be-a2c5-a513ea1571693280Chiropractic Spinal and Extraspinal Manipulation Therapy10.02.02
587df3b8-62b9-4b9f-9077-c749915aa179.aspx
  
08.00.92adCoagulationFactors08.00.92adPharmacy (08)Coagulation Factors 587df3b8-62b9-4b9f-9077-c749915aa1793719Coagulation Factors 08.00.92
28b7bded-e653-48c9-8ce4-55585b9d0a5a.aspx
  
06.02.54bCobalamin(VitaminB12),FolicAcid,andHomocysteineTesting06.02.54bPathology and Laboratory (06)Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing28b7bded-e653-48c9-8ce4-55585b9d0a5a3841Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing06.02.54
{"3842": {"Id":3842,"MPAttachmentLetter":"A","Title":"MEDICALLY NECESSARY ICD 10 CODES FOR COBALAMIN (VITAMIN B12) AND/OR FOLIC ACID TESTING (CPT CODES 82607, 82608, 82746, AND 82747)","MPPolicyAttachmentInternalSourceId":6108,"PolicyAttachmentPageName":"8bfa343e-fd32-44e5-bb8b-2708d310b6e4"},}
52e574a3-d754-4e64-ae47-a5d0662891ef.aspx
  
11.01.02pCochlearImplant11.01.02pSurgery (11)Cochlear Implant52e574a3-d754-4e64-ae47-a5d0662891ef3123Cochlear Implant11.01.02
e099201b-9a35-4d40-a33e-66396302d48e.aspx
  
08.01.71Collagenaseclostridiumhistolyticum(Xiaflex®),collagenaseclostridiumhistolyticum-aaes(Qwo™)08.01.71Pharmacy (08)Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™)e099201b-9a35-4d40-a33e-66396302d48e3458Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™)08.01.71
b13222a3-3284-42ca-b079-b34f15e94d7a.aspx
  
11.03.12tColorectalCancerScreening11.03.12tSurgery (11)Colorectal Cancer Screeningb13222a3-3284-42ca-b079-b34f15e94d7a3843Colorectal Cancer Screening11.03.12
B55889244594F1F085258574005DA579.aspx
  
12.00.03gComplementary and Integrative Health ServicesMiscellaneous (12)Complementary and Integrative Health ServicesB55889244594F1F085258574005DA5792104Complementary and Integrative Health Services12.00.03
74d20bbd-cd53-4d56-b994-33ea919b217c.aspx
  
07.06.01bCompleteDecongestiveTherapy(CDT)07.06.01bMedicine (07)Complete Decongestive Therapy (CDT)74d20bbd-cd53-4d56-b994-33ea919b217c3330Complete Decongestive Therapy (CDT)07.06.01
cfc67080-f181-438d-9190-d1df58f6bc1d.aspx
  
11.14.30CompositeTissueAllotransplantationoftheHand(s)andFace11.14.30Surgery (11)Composite Tissue Allotransplantation of the Hand(s) and Facecfc67080-f181-438d-9190-d1df58f6bc1d3197Composite Tissue Allotransplantation of the Hand(s) and Face11.14.30
edddd201-1bf2-479f-9f86-1fd2713538d5.aspx
  
05.00.37fCompressionGarments05.00.37fDME (05)Compression Garmentsedddd201-1bf2-479f-9f86-1fd2713538d53195Compression Garments05.00.37
f076fe82-4422-4ecd-b854-e6d0a1f17257.aspx
  
09.00.42cComputer-AidedDetection(CAD)SystemforUsewithChestRadiographs09.00.42cRadiology (09)Computer-Aided Detection (CAD) System for Use with Chest Radiographsf076fe82-4422-4ecd-b854-e6d0a1f172573524Computer-Aided Detection (CAD) System for Use with Chest Radiographs09.00.42
997a85b5-16c6-4037-9e9a-30ef7a8f47c8.aspx
  
11.14.17eComputer-assistedMusculoskeletalSurgicalNavigationalOrthopedicProcedure11.14.17eSurgery (11)Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure997a85b5-16c6-4037-9e9a-30ef7a8f47c83199Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure11.14.17
F3BA7DB0E980312B8525854B005EE64C.aspx
  
00.01.69Consultation ServicesAdministrative (00)Consultation ServicesF3BA7DB0E980312B8525854B005EE64C2172Consultation Services00.01.69
de4b9003-d385-4e53-a6ac-09b1580bf18b.aspx
  
07.13.11kContactLensesfortheTreatmentofPersistent(Corneal)EpithelialDefects07.13.11kMedicine (07)Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defectsde4b9003-d385-4e53-a6ac-09b1580bf18b3786Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects07.13.11
{"3787": {"Id":3787,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5954,"PolicyAttachmentPageName":"5220bf21-251e-4704-aad8-af351e7f81f9"},}
486b7833-e733-47e1-a5a2-1fb22d353084.aspx
  
09.00.11eContrastAgentsUsedinConjunctionwithEchocardiography09.00.11eRadiology (09)Contrast Agents Used in Conjunction with Echocardiography486b7833-e733-47e1-a5a2-1fb22d3530843091Contrast Agents Used in Conjunction with Echocardiography09.00.11
3a53de9a-2697-4ac6-bf3e-2a41634f3e01.aspx
  
07.13.07kCornealPachymetryUsingUltrasound07.13.07kMedicine (07)Corneal Pachymetry Using Ultrasound3a53de9a-2697-4ac6-bf3e-2a41634f3e013773Corneal Pachymetry Using Ultrasound07.13.07
{"3774": {"Id":3774,"MPAttachmentLetter":"A","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":5964,"PolicyAttachmentPageName":"2fb4f87e-3363-42ab-af80-ce4de752fcb9"},}
70aeb740-4e46-455e-abef-c6d9421a64e8.aspx
  
12.01.03aCosmeticProcedures12.01.03aMiscellaneous (12)Cosmetic Procedures70aeb740-4e46-455e-abef-c6d9421a64e83329Cosmetic Procedures12.01.03
1cb1a28f-8e36-42f3-803c-ad161ab1f64c.aspx
  
08.01.08gCoverageofAnticancerPrescriptionOralandInjectableDrugsandBiologicsandSupportiveAgents08.01.08gPharmacy (08)Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents1cb1a28f-8e36-42f3-803c-ad161ab1f64c3960Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents08.01.08
{}
0e5a3246-799b-4df3-bc4a-9a5c0ec82166.aspx
  
05.00.04eCoverageofMedicalDevices05.00.04eDME (05)Coverage of Medical Devices0e5a3246-799b-4df3-bc4a-9a5c0ec821663665Coverage of Medical Devices05.00.04
d99f515d-cb84-427a-b2a9-e637825a0198.aspx
  
05.00.80aCranialElectrotherapyStimulation05.00.80aDME (05)Cranial Electrotherapy Stimulationd99f515d-cb84-427a-b2a9-e637825a01983810Cranial Electrotherapy Stimulation05.00.80
81e6e200-2094-43e9-804d-25c02aa5f8bf.aspx
  
05.00.25iCranialRemoldingOrthoses(Helmets)05.00.25iDME (05)Cranial Remolding Orthoses (Helmets)81e6e200-2094-43e9-804d-25c02aa5f8bf2998Cranial Remolding Orthoses (Helmets)05.00.25
85256AA800623D7A852584710058EC0E.aspx
  
00.10.03jCriteria for Reimbursement of Emergency Room ServicesAdministrative (00)Criteria for Reimbursement of Emergency Room Services85256AA800623D7A852584710058EC0E2001Criteria for Reimbursement of Emergency Room Services00.10.03
f6a258a4-1a08-4ad9-aee7-39f1f23d4fb6.aspx
  
08.00.04crizanlizumab-tmca(Adakveo®)08.00.04Pharmacy (08)crizanlizumab-tmca (Adakveo®)f6a258a4-1a08-4ad9-aee7-39f1f23d4fb63175crizanlizumab-tmca (Adakveo®)08.00.04
6398d8a3-6df3-482a-8408-a2ac2e2ee22b.aspx
  
11.11.03dCryosurgicalAblationoftheProstateGland11.11.03dSurgery (11)Cryosurgical Ablation of the Prostate Gland6398d8a3-6df3-482a-8408-a2ac2e2ee22b3203Cryosurgical Ablation of the Prostate Gland11.11.03
c52b181a-c56d-458d-b762-7932fdcf8937.aspx
  
08.01.29iDaratumumab(Darzalex®),Daratumumab,andHyaluronidase-fihj(DarzalexFaspro®)08.01.29iPharmacy (08)Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®)c52b181a-c56d-458d-b762-7932fdcf89373289Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®)08.01.29
7af90fad-1979-498e-98f3-5da73f3bfad9.aspx
  
10.00.02cDayRehabilitation10.00.02cRehabilitation Services (10)Day Rehabilitation7af90fad-1979-498e-98f3-5da73f3bfad93351Day Rehabilitation10.00.02
e3eb36bf-27fc-4bb7-aff5-6392d35d8cfe.aspx
  
11.08.17kDebridementofMycoticandSymptomaticNon-MycoticHypertrophicToeNails11.08.17kSurgery (11)Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nailse3eb36bf-27fc-4bb7-aff5-6392d35d8cfe3609Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails11.08.17
{"3610": {"Id":3610,"MPAttachmentLetter":"E","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (S86.892A - Z79.01), Continued","MPPolicyAttachmentInternalSourceId":5830,"PolicyAttachmentPageName":"47c3847f-3512-4996-8ae4-d969b12de906"},"3611": {"Id":3611,"MPAttachmentLetter":"D","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (I87.099 - S86.891S), Continued","MPPolicyAttachmentInternalSourceId":5831,"PolicyAttachmentPageName":"d31c3e08-8923-4e3b-a452-c413b6846627"},"3612": {"Id":3612,"MPAttachmentLetter":"C","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E13.3513 - I87.093), Continued","MPPolicyAttachmentInternalSourceId":5832,"PolicyAttachmentPageName":"3da31121-131b-49c8-b4b3-4c849684a0f6"},"3613": {"Id":3613,"MPAttachmentLetter":"B","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E10.22 - E13.3512), Continued","MPPolicyAttachmentInternalSourceId":5833,"PolicyAttachmentPageName":"cf173c8f-936f-4cd4-908e-4add60b9ed31"},"3614": {"Id":3614,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (A30.0 -E10.21)","MPPolicyAttachmentInternalSourceId":5834,"PolicyAttachmentPageName":"987ca92f-46fc-43f6-8bf7-3d3a9d6b601c"},}
5ca29d9a-b491-4574-8883-a34fa8efdba8.aspx
  
11.15.20pDeepBrainStimulation(DBS)11.15.20pSurgery (11)Deep Brain Stimulation (DBS)5ca29d9a-b491-4574-8883-a34fa8efdba83728Deep Brain Stimulation (DBS)11.15.20
f30d1c58-12ed-4dd7-804a-44b17a3f3141.aspx
  
11.15.09pDenervationoftheSpinalNervesforChronicPain(IndependenceAdministrators)11.15.09pSurgery (11)Denervation of the Spinal Nerves for Chronic Pain (Independence Administrators)f30d1c58-12ed-4dd7-804a-44b17a3f31413772Denervation of the Spinal  Nerves for Chronic Pain (Independence Administrators)11.15.09
0f6392a1-2719-450d-980d-71109cfbbf99.aspx
  
08.00.94oDenosumab(Prolia®,Xgeva®),Romosozumab-aqqg(Evenity®)08.00.94oPharmacy (08)Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®)0f6392a1-2719-450d-980d-71109cfbbf993185Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®)08.00.94
{"3186": {"Id":3186,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes","MPPolicyAttachmentInternalSourceId":5349,"PolicyAttachmentPageName":"1cf1d69b-23e3-49fb-82c0-805cfc574fa9"},}
04806458-c6be-4c07-9ca9-0fde63e8263b.aspx
  
11.16.01iDermabrasionforRhinophyma,Septoplasty,Rhinoplasty,andSeptorhinoplasty11.16.01iSurgery (11)Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty04806458-c6be-4c07-9ca9-0fde63e8263b3928Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty11.16.01
446bbd29-dbdd-4b22-9e4d-36459520ca1e.aspx
  
00.03.02acDiagnosticRadiologyServicesIncludedinCapitation00.03.02acAdministrative (00)Diagnostic Radiology Services Included in Capitation446bbd29-dbdd-4b22-9e4d-36459520ca1e3997Diagnostic Radiology Services Included in Capitation00.03.02
{"3998": {"Id":3998,"MPAttachmentLetter":"A","Title":"Diagnostic Radiology Procedure Codes Included in Capitation for Pennsylvania (PA) Health Maintenance Organization (HMO) Members","MPPolicyAttachmentInternalSourceId":6155,"PolicyAttachmentPageName":"b5a08986-de39-403a-8a4b-0fc9ce6f7f1e"},}
f1e8356b-0be8-4ff2-ab3e-8a379e2b7649.aspx
  
00.09.01iDirectAccesstoObstetrics/Gynecology(OB/GYN)Services00.09.01iAdministrative (00)Direct Access to Obstetrics/Gynecology (OB/GYN) Servicesf1e8356b-0be8-4ff2-ab3e-8a379e2b76493994Direct Access to Obstetrics/Gynecology (OB/GYN) Services00.09.01
{}
dbbe3feb-80d9-4d66-bbd2-6135accf52d1.aspx
  
08.00.49eDofetilide(Tikosyn®)UseintheInpatientSetting08.00.49ePharmacy (08)Dofetilide (Tikosyn®) Use in the Inpatient Settingdbbe3feb-80d9-4d66-bbd2-6135accf52d13210Dofetilide (Tikosyn®) Use in the Inpatient Setting08.00.49
a4999973-36c4-48cf-8e76-69b8c034e086.aspx
  
08.01.79bDostarlimab-gxly(Jemperli)08.01.79bPharmacy (08)Dostarlimab-gxly (Jemperli)a4999973-36c4-48cf-8e76-69b8c034e0863963Dostarlimab-gxly (Jemperli)08.01.79
73cccc6d-90e9-4c06-b4b7-5b1be78578a5.aspx
  
07.05.07dDrug-ElutingBeadsandBlandEmbolizationfortheTreatmentofHepaticMalignancies07.05.07dMedicine (07)Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies73cccc6d-90e9-4c06-b4b7-5b1be78578a53705Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies07.05.07
1f4283fc-5e91-48fe-a0ec-deae8a129738.aspx
  
08.01.37aDrugsUsedfortheMaintenanceTreatmentofOpioidorAlcoholUseDisorder(e.g.,NaltrexoneImplants,ProbuphineImplant,SublocadeInjection,VivitrolInjection)08.01.37aPharmacy (08)Drugs Used for the Maintenance Treatment of Opioid or Alcohol Use Disorder (e.g., Naltrexone Implants, Probuphine Implant, Sublocade Injection, Vivitrol Injection)1f4283fc-5e91-48fe-a0ec-deae8a1297383479Drugs Used for the Maintenance Treatment of Opioid or Alcohol Use Disorder (e.g., Naltrexone Implants, Probuphine Implant, Sublocade Injection, Vivitrol Injection)08.01.37
1 - 100Next